Literature DB >> 10580045

Expression of bovine viral diarrhoea virus glycoprotein E2 by bovine herpesvirus-1 from a synthetic ORF and incorporation of E2 into recombinant virions.

Jutta Schmitt1, Paul Becher2, Heinz-Jürgen Thiel2, Günther M Keil1.   

Abstract

Expression cassettes containing the codons for the pestivirus E (rns) signal peptide (Sig) followed by a chemically synthesized ORF that encoded the bovine viral diarrhoea virus (BVDV) strain C86 glycoprotein E2, a class I membrane glycoprotein, were constructed with and without a chimeric intron sequence immediately upstream of the translation start codon, and incorporated into the genome of bovine herpesvirus-1 (BHV-1). The resulting recombinants, BHV- 1/SigE2(syn) and BHV-1/SigE2(syn)-intron, expressed comparable quantities of glycoprotein E2, and Northern blot hybridizations indicated that the presence of the intron did not increase significantly the steady-state levels of transcripts encompassing the SigE2(syn) ORF. In BHV-1/SigE2(syn)- infected cells, the 54 kDa E2 glycoprotein formed a dimer with an apparent molecular mass of 94 kDa, which was further modified to a 101 kDa form found in the envelope of recombinant virus particles. Penetration kinetics and single-step growth curves indicated that the incorporation of the BVDV E2 glycoprotein in the BHV-1 envelope, which apparently did not require BHV-1-specific signals, interfered with entry into target cells and egress of progeny virions. These results demonstrate that a pestivirus glycoprotein can be expressed efficiently by BHV-1 and incorporated into the viral envelope. BHV-1 thus represents a promising tool for the development of efficacious live and inactivated BHV-1-based vector vaccines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10580045     DOI: 10.1099/0022-1317-80-11-2839

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Safety and efficacy of an E2 glycoprotein subunit vaccine produced in mammalian cells to prevent experimental infection with bovine viral diarrhoea virus in cattle.

Authors:  Andrea Pecora; María Sol Pérez Aguirreburualde; Alejandra Aguirreburualde; Maria Rosa Leunda; Anselmo Odeon; Sebastián Chiavenna; Diego Bochoeyer; Marcelo Spitteler; Jorge L Filippi; Maria J Dus Santos; Susana M Levy; Andrés Wigdorovitz
Journal:  Vet Res Commun       Date:  2012-05-26       Impact factor: 2.459

2.  Expression of the genomic form of the bovine viral diarrhea virus E2 ORF in a bovine herpesvirus-1 vector.

Authors:  Lingshu Wang; J Charles Whitbeck; William C Lawrence; Denys V Volgin; Leonard J Bello
Journal:  Virus Genes       Date:  2003-08       Impact factor: 2.332

3.  A hepadnavirus regulatory element enhances expression of a type 2 bovine viral diarrhea virus E2 protein from a bovine herpesvirus 1 vector.

Authors:  Lingshu Wang; Sreekumar Menon; Steven R Bolin; Leonard J Bello
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

4.  Construction and manipulation of an infectious clone of the bovine herpesvirus 1 genome maintained as a bacterial artificial chromosome.

Authors:  Timothy J Mahony; Fiona M McCarthy; Jennifer L Gravel; Lani West; Peter L Young
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

5.  BoHV-1-Vectored BVDV-2 Subunit Vaccine Induces BVDV Cross-Reactive Cellular Immune Responses and Protects against BVDV-2 Challenge.

Authors:  Shafiqul I Chowdhury; Katrin Pannhorst; Neha Sangewar; Selvaraj Pavulraj; Xue Wen; Rhett W Stout; Waithaka Mwangi; Daniel B Paulsen
Journal:  Vaccines (Basel)       Date:  2021-01-13

6.  Recombinant Bovine Herpesvirus Type I Expressing the Bovine Viral Diarrhea Virus E2 Protein Could Effectively Prevent Infection by Two Viruses.

Authors:  Chun-Yu Liu; Hao Guo; Hong-Zhe Zhao; Li-Na Hou; Yong-Jun Wen; Feng-Xue Wang
Journal:  Viruses       Date:  2022-07-25       Impact factor: 5.818

Review 7.  Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.

Authors:  Alejandro Brun; Emmanuel Albina; Tom Barret; David A G Chapman; Markus Czub; Linda K Dixon; Günther M Keil; Bernard Klonjkowski; Marie-Frédérique Le Potier; Geneviève Libeau; Javier Ortego; Jennifer Richardson; Haru-H Takamatsu
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

Review 8.  Immunoprophylaxis against important virus disease of horses, farm animals and birds.

Authors:  J R Patel; J G M Heldens
Journal:  Vaccine       Date:  2009-03-13       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.